Tomasz (Tom) Beer

Professor

  • 14418 Citations
  • 53 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2000 2019

Filter
Comment/debate
2019

Combining options in metastatic prostate cancer

Kopp, R. & Beer, T. T., Jan 1 2019, In : Nature Reviews Urology.

Research output: Contribution to journalComment/debate

Prostatic Neoplasms
docetaxel
Therapeutics

Correction: Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer (Clinical Cancer Research (2019) 25 (52-63) DOI: 10.1158/1078-0432.CCR-18-1589)

Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Apr 15 2019, In : Clinical Cancer Research. 25, 8, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Castration
Epigenomics
Prostatic Neoplasms
Emotions
Research

Erratum to: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy (Nature Communications, (2018), 9, 1, (4972), 10.1038/s41467-018-07411-7)

Geng, H., Xue, C., Mendonca, J., Sun, X-X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. T., Dai, M., Kachhap, S. K. & Qian, Z. D., Dec 1 2019, In : Nature Communications. 10, 1, 164.

Research output: Contribution to journalComment/debate

hypoxia
Androgens
therapy
switches
communication
2018
6 Citations (Scopus)

Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. T., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Oct 18 2018, In : Cell. 175, 3, 1 p.

Research output: Contribution to journalComment/debate

Genomic Structural Variation
Manuscripts
Amplification
Prostatic Neoplasms
Statistical tests
2014
23 Citations (Scopus)

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer, T. T. & Tombal, B., Jan 1 2014, In : The New England journal of medicine. 371, 18, p. 1755-1756 2 p.

Research output: Contribution to journalComment/debate

Hormonal Antineoplastic Agents
Phenylthiohydantoin
Androgen Receptor Antagonists
Prostatic Neoplasms
Adenocarcinoma